US2017002051A1PendingUtilityA1
Avian colony stimulating factor 1 receptor binding proteins
Assignee: UNIV COURT UNIV OF EDINBURGHPriority: Jun 23, 2009Filed: Jul 11, 2016Published: Jan 5, 2017
Est. expiryJun 23, 2029(~2.9 yrs left)· nominal 20-yr term from priority
A61P 29/00C07K 14/53A61K 38/193C12Q 2600/158C07K 14/54A61K 38/00C12N 15/63C12Q 2600/156A61K 2039/55522C12N 15/09A61K 2039/55527A61K 39/39C12Q 1/6888
32
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides avian CSF1 genes encoding proteins which bind avian colony stimulating factor 1 receptor (CSF1R) and which exhibit immunomodulatory properties.
Claims
exact text as granted — not AI-modified1 - 9 . (canceled)
10 . A method of modulating avian growth and/or organ development comprising administering an effective amount of an avian CSF1 and/or IL34 gene and/or protein to an avian subject.
11 - 15 . (canceled)
16 . A method of modulating the avian immune system comprising administering an immunomodulatory amount of an avian CSF1 and/or IL34 gene and/or protein to an avian subject.
17 . A vaccine adjuvant comprising an avian CSF1 and IL34 protein.
18 . The vaccine adjuvant of claim 17 , wherein the avian CSF1 protein, comprises an amino acid sequence at least 60% identical or homologous to the amino acid sequences of SEQ ID NOS:3 or 5.
19 . An immunogenic composition, comprising an avian CSF1 and/or IL34 protein.
20 . A method of treating conditions, such as inflammatory diseases, resulting from or associated with aberrant CSF1/IL34 gene/protein expression, said method comprising an effective amount of a compound capable of inhibiting CSF1/IL34 gene expression or protein production to an avian subject.
21 . The method of claim 20 , wherein the compound is selected from the group consisting of: a sense or antisense nucleic acid molecule; a fragment, portion or derivative of an avian CSF1/IL34 gene; and an antibody.
22 . A method of screening avian species, particularly agriculturally significant or important avian species for potential inclusion in breeding programs said method comprising the steps of:
a) providing a nucleic acid sample from an avian species; and b) comparing the level of expression of the CSF1 and/or IL34 gene(s) with a reference nucleic acid sample or value;
wherein avian species which exhibit and increased level of CSF1 and/or IL34 gene expression relative to a that present in a reference nucleic acid sample or value, may be selected for inclusion in breeding programs.
23 . An avian CSF1 gene comprising a nucleic acid sequence at least 60% identical or homologous to the nucleic acid sequences of SEQ ID NOS: 1, 2 or 4.
24 . A fragment, analogue, portion, mutant, variant, derivative and/or homologue/orthologue of the gene of claim 23 .
25 . An avian IL34 gene comprising a nucleic acid sequence at least 60% identical or homologous to the nucleic acid sequence of SEQ ID NO:6.
26 . A fragment, analogue, portion, mutant, variant, derivative and/or homologue/orthologue of the gene of claim 25 .
27 . A substantially purified avian CSF1 protein, comprising an amino acid sequence at least 60% identical or homologous to the amino acid sequences of SEQ ID NOS:3 or 5.
28 . A fragment, analogue, portion, mutant, variant, derivative and/or homologue/orthologue of the protein of claim 27 .
29 . A substantially purified avian IL34 protein, comprising an amino acid sequence at least 60% identical or homologous to the amino acid sequence of SEQ ID NO:6.
30 . A fragment, analogue, portion, mutant, variant, derivative and/or homologue/orthologue of the protein of claim 29 .
31 . An expression vector comprising an avian CSF1 gene sequence or fragment or portion thereof.
32 . The expression vector of claim 31 , wherein the avian gene sequence comprises a nucleic acid sequence at least 60% identical or homologous to the nucleic acid sequences of SEQ ID NOS:1, 2 or 4.
33 . An expression vector comprising an avian IL34 gene sequence or fragment or portion thereof.
34 . The expression vector of claim 33 , wherein the avian IL34 gene sequence comprises a nucleic acid sequence at least 60% identical or homologous to the nucleic acid sequence of SEQ ID NO:6.
35 . A host cell transformed with the expression vector of claim 31 .
36 . A host cell transformed with the expression vector of claim 32 .
37 . A host cell transformed with the expression vector of claim 33 .Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.